Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1CNS 1

Conditions

Oligodendroglioma 1Lymphoma, Follicular 1Glioma 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 4vorasidenib 2Lomustine 2Blood Specimen Collection 2trametinib 1tovorafenib 1posaconazole 1perillyl alcohol 1pembrolizumab 1niraparib 1mirdametinib 1gallium maltolate 1dabrafenib 1cemiplimab 1Urination 1Transurethral Resection of Bladder 1Standard of Care 1Spinal Puncture 1Specimen Handling 1Sitagliptin Phosphate 1Receptors, Interleukin-8B 1Radiotherapy 1Radiation 1Positron Emission Tomography Computed Tomography 1Physical Therapy Modalities 1Mental Status and Dementia Tests 1Magnetic Resonance Spectroscopy 1Magnetic Resonance Imaging 1Ketoconazole 1Histocompatibility Testing 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Glioma × Eflornithine × Clear all
NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Mayo Clinic

Phase 1/2 Not yet recruiting
33 enrolled
CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡